Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

BACKGROUND: Chronic myeloid leukemia is successfully managed by imatinib therapy, but the question remains whether treatment must be administered indefinitely. Imatinib discontinuation trials have led to two distinct outcomes: about 60% of patients experienced disease relapse within 6 months of trea...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Tang, Min, Foo, Jasmine, Gönen, Mithat, Guilhot, Joëlle, Mahon, François-Xavier, Michor, Franziska
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2012
נושאים:
Original Articles and Brief Reports
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3487556/
https://ncbi.nlm.nih.gov/pubmed/22419579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.062844
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים